Health News Releases

  • Today May 22
June 19, 2015 14:40
Gore Global Registry for Endovascular Aortic Treatment Enrolls 3,000 Patients
W. L. Gore & Associates, Inc. (www.goremedical.com) (Gore) announced that important updates from the Gore Global Registry for Endovascular Aortic Treatment (GREAT) will be presented today at the 2015
June 17, 2015 11:55
Cook Group President Kem Hawkins to Retire in July
Cook Group announced today that Kem Hawkins, president of Cook Group Incorporated, will retire on July 1 after 34 years with the Cook organization. Hawkins, who has been transitioning his role in the
June 16, 2015 17:20
New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers
Today, The Lancet published results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate) by its specific reversal agent idarucizumab
June 16, 2015 13:35
Quintiles Unveils New Predictive and Advanced Analytics Capabilities to Enhance its Risk-Based Monitoring Solution
Quintiles, the world’s largest biopharmaceutical services company, today announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (R
June 11, 2015 11:45
Bioventus Leaders Promoted to Manage International Business and Expansion
Bioventus® (www.bioventusglobal.com), a leader in orthobiologic solutions, today announced promotions to its executive leadership team. Effective immediately Andrew Hosmer is promoted to Managing Dire
June 10, 2015 09:40
Oral Presentation Evaluating Pooled Data on OTEZLA® (apremilast) for Long-Term Improvements in Enthesitis and Dactylitis to Be Presented at EULAR
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the findings from a long-term (104-week) post-hoc analysis of pooled data from the PALA
June 08, 2015 17:50
Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care
New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed (‘add-on’), is linked to future patient self-c
June 08, 2015 17:45
Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA
A Phase III clinical trial has found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes (T2D). Boehringer Ingelheim and Eli Lilly and Company
June 08, 2015 11:35
HOYA Group PENTAX Medical Launches Splash M-Knife, the New Multi-Functional ESD Device Contributing in Early Treatment of Gastric Cancer
HOYA Group PENTAX Medical launches Splash M-Knife, the new multi-functional ESD Device to achieve complete Endoscopic Submucosal Dissection (ESD herein after) with a single device. The new device will
June 08, 2015 11:10
Quintiles Officially Opens Greater China Regional Headquarters in Shanghai
More than 30 leaders from China’s government and healthcare communities joined Quintiles executives here today in officially opening the Quintiles Greater China Regional Headquarters, further expandin
June 04, 2015 15:50
Celgene Announces New Data to be Presented at European League Against Rheumatism Annual Congress
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that data from 11 abstracts (two oral presentations, six poster presentations and three publ
June 03, 2015 18:10
NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication
Boehringer Ingelheim today announced that following a review by the National Institute for Health and Care Excellence (NICE) in the UK, VARGATEF® (nintedanib*) in combination with docetaxel has been r
June 03, 2015 14:25
Trophogen, Inc. Announces Signing of Exclusive Global Veterinary License and Purchase Agreement With Zoetis, Inc. for Recombinant Long-Acting and Superactive Bovine Follicle-Stimulating Hormone (rbFSH) Analog for Superovulation in Cows
Trophogen, Inc. today announced that the company has completed a licensing and purchase agreement granting Zoetis, Inc., the leading global animal health company, an exclusive license to develop Troph
June 01, 2015 10:00
ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 (https://goo.gl/6xNSFt) trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed t
May 29, 2015 09:30
Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union
Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combinat
May 28, 2015 10:45
Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance portfolio June 5-9 at the American Diabetes Association’
May 27, 2015 09:25
FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved
May 26, 2015 14:00
Quintiles Launches New Solution to Meet Needs of Asia-Pacific Emerging Biopharmaceutical Companies
To help Asia-Pacific emerging biopharmaceutical companies achieve their growth aspirations, Quintiles today launched a new solution set tailored to meet the needs of emerging companies in the world’s
May 26, 2015 11:40
Cook Medical Welcomes Progressive Medical Device Single Audit Program
Cook Medical is pleased to be one of the global medical device companies to collaborate internationally with regulatory authorities on the Medical Device Single Audit Program (MDSAP). The value of
May 21, 2015 11:55
New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy[1,2,3]
Boehringer Ingelheim today announced new data analyses from the pivotal Phase III TONADO® 1&2 studies[4] (NCT01431274, https://goo.gl/7NI8eq / NCT01431287, https://goo.gl/ug1HN1). Data showed tiotropi
May 20, 2015 10:55
Analysis of Phase II Data for Celgene’s Investigational Oral GED-0301 in Patients with Active Crohn’s Disease Presented at Digestive Disease Week
Celgene Corporation (NASDAQ: CELG) today announced that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients w
May 19, 2015 15:00
Presentation at International Headache Congress shows electroCore’s chronic cluster headache treatment to be cost-effective
A poster at the International Headache Society meeting in Valencia, Spain, demonstrated that treatment with electroCore’s nVNS treatment for chronic cluster headache, gammaCore, was both clinically an
May 18, 2015 18:20
Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the t
May 18, 2015 18:15
New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups
Boehringer Ingelheim announced new data and analyses for OFEV® (nintedanib*) reinforcing its efficacy, safety and tolerability in a broad range of patients with idiopathic pulmonary fibrosis (IPF). Th
May 14, 2015 15:45
Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung
Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, 29 Ma
25 per page50 per page75 per page100 per page